Bank of New York Mellon Corp lowered its holdings in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 0.6% in the first quarter, HoldingsChannel.com reports. The fund owned 678,749 shares of the medical research company’s stock after selling 3,998 shares during the quarter. Bank of New York Mellon Corp’s holdings in PRA Health Sciences were worth $56,364,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC raised its position in PRA Health Sciences by 4.4% during the fourth quarter. Geode Capital Management LLC now owns 717,352 shares of the medical research company’s stock worth $79,733,000 after acquiring an additional 30,111 shares during the last quarter. Natixis Advisors L.P. raised its position in PRA Health Sciences by 25.0% during the first quarter. Natixis Advisors L.P. now owns 55,521 shares of the medical research company’s stock worth $4,610,000 after acquiring an additional 11,110 shares during the last quarter. FMR LLC raised its position in PRA Health Sciences by 136.4% during the fourth quarter. FMR LLC now owns 269,632 shares of the medical research company’s stock worth $29,970,000 after acquiring an additional 155,591 shares during the last quarter. AXA acquired a new position in PRA Health Sciences during the fourth quarter worth about $211,000. Finally, Norges Bank acquired a new position in PRA Health Sciences during the fourth quarter worth about $70,478,000. Institutional investors own 97.29% of the company’s stock.

In related news, CFO Michael J. Bonello sold 3,672 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $87.97, for a total value of $323,025.84. Following the completion of the transaction, the chief financial officer now owns 23,328 shares in the company, valued at approximately $2,052,164.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.30% of the company’s stock.

Shares of PRAH opened at $96.63 on Friday. The firm has a 50-day moving average price of $87.42 and a 200 day moving average price of $97.96. The firm has a market capitalization of $5.88 billion, a PE ratio of 26.40 and a beta of 1.09. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 1.30. PRA Health Sciences Inc has a 52-week low of $58.67 and a 52-week high of $113.10.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Thursday, April 30th. The medical research company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.01 by $0.04. The firm had revenue of $783.71 million during the quarter, compared to analyst estimates of $749.61 million. PRA Health Sciences had a net margin of 7.66% and a return on equity of 27.59%. PRA Health Sciences’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.10 EPS. On average, equities analysts expect that PRA Health Sciences Inc will post 3.67 EPS for the current year.

A number of equities analysts have issued reports on PRAH shares. Jefferies Financial Group cut their target price on shares of PRA Health Sciences from $125.00 to $89.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. BidaskClub upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Friday, May 1st. Zacks Investment Research upgraded shares of PRA Health Sciences from a “sell” rating to a “hold” rating and set a $99.00 price target for the company in a report on Tuesday. Wolfe Research downgraded shares of PRA Health Sciences from an “outperform” rating to a “market perform” rating and set a $97.00 price target for the company. in a report on Monday, April 13th. Finally, Citigroup lowered their price target on shares of PRA Health Sciences from $120.00 to $90.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $100.82.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Recommended Story: How are dividend achievers different from dividend aristocrats?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.